In conclusion, we have discovered a new, acquired vulnerability in NSCLC associated with LKB1/STK11 mutations in a subset of NSCLCs that is represented by GR agonist induced CDKN1C expression leading to a host of anti-tumor responses. Here, CDKN1C is linked to non-small cell lung carcinoma.